Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2002 1
2003 1
2006 2
2007 1
2011 1
2013 3
2014 3
2015 4
2016 1
2017 1
2018 2
2019 3
2020 7
2021 5
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
Takeuchi Y, Nouso K, Fujioka SI, Kariyama K, Kobashi H, Uematsu S, Moriya A, Hagihara H, Takabatake H, Nakamura S, Yabushita K, Kikuchi T, Oyama A, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A. Takeuchi Y, et al. Among authors: moriya a. Cancer Med. 2023 Sep;12(17):17559-17568. doi: 10.1002/cam4.6369. Epub 2023 Aug 3. Cancer Med. 2023. PMID: 37537956 Free PMC article.
Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study.
Morishita A, Oura K, Takuma K, Nakahara M, Tadokoro T, Fujita K, Tani J, Shi T, Himoto T, Tatsuta M, Moriya A, Senoo T, Tsutsui A, Nagano T, Takaguchi K, Ono M, Masaki T. Morishita A, et al. Among authors: moriya a. Hepatol Int. 2023 Jun;17(3):606-614. doi: 10.1007/s12072-022-10453-1. Epub 2022 Dec 30. Hepatol Int. 2023. PMID: 36583842 Free PMC article.
Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy.
Oura K, Morishita A, Manabe T, Takuma K, Nakahara M, Tadokoro T, Fujita K, Mimura S, Tani J, Ono M, Ogawa C, Moriya A, Senoo T, Tsutsui A, Nagano T, Takaguchi K, Himoto T, Masaki T. Oura K, et al. Among authors: moriya a. Cancers (Basel). 2023 Jun 19;15(12):3243. doi: 10.3390/cancers15123243. Cancers (Basel). 2023. PMID: 37370853 Free PMC article.
Time-course changes in liver functional reserve after successful sofosbuvir/velpatasvir treatment in patients with decompensated cirrhosis.
Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asano T, Ogawa C, Abe H, Kato K, Hotta N, Shima T, Matsuura K, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Morishita A, Hidaka I, Moriya A, Tsuji K, Akahane T, Okubo T, Arai T, Kitamura M, Morita K, Kawata K, Tanaka Y, Kumada T, Iwakiri K; KTK49 Liver Study Group. Atsukawa M, et al. Among authors: moriya a. Hepatol Res. 2022 Mar;52(3):235-246. doi: 10.1111/hepr.13739. Epub 2021 Dec 17. Hepatol Res. 2022. PMID: 34861090
Entecavir Reduces Hepatocarcinogenesis in Chronic Hepatitis B Patients.
Yasunaka T, Ikeda F, Wada N, Morimoto Y, Fujioka S, Toshimori J, Kobashi H, Kariyama K, Morimoto Y, Takayama H, Seno T, Takaguchi K, Moriya A, Miyatake H, Okamoto R, Yabushita K, Takaki A, Yamamoto K. Yasunaka T, et al. Among authors: moriya a. Acta Med Okayama. 2016;70(1):1-12. doi: 10.18926/AMO/53996. Acta Med Okayama. 2016. PMID: 26899604 Free article.
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Tomonari T, Tani J, Ogawa C, Deguchi A, Senoh T, Moriya A, Shibata H, Fukuno H, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Kawano Y, Morishita A, Takaguchi K, Miyamoto H, Sato Y, Masaki T, Takayama T. Tomonari T, et al. Among authors: moriya a. Hepatol Res. 2023 Feb;53(2):172-178. doi: 10.1111/hepr.13845. Epub 2022 Oct 18. Hepatol Res. 2023. PMID: 36214071
Misunderstanding of hepatitis C virus (HCV) infection status by non-specialized medical doctors in patients who achieved sustained virologic response to anti-HCV therapy.
Toyoda H, Yasuda S, Moriya A, Itobayashi E, Uojima H, Watanabe T, Atsukawa M, Arai T, Ishikawa T, Mikami S, Hiraoka A, Tsuji K, Oikawa T, Tsubota A, Nozaki A, Chuma M, Abe H, Shima T, Kumada T, Tanaka J. Toyoda H, et al. Among authors: moriya a. J Infect Chemother. 2022 Sep;28(9):1231-1234. doi: 10.1016/j.jiac.2022.04.024. Epub 2022 May 6. J Infect Chemother. 2022. PMID: 35534339
Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
Kikuchi T, Takeuchi Y, Nouso K, Kariyama K, Kuwaki K, Toshimori J, Iwado S, Moriya A, Hagihara H, Takabatake H, Tada T, Yasunaka T, Sakata M, Sue M, Miyake N, Adachi T, Wada N, Onishi H, Shiraha H, Takaki A, Otsuka M. Kikuchi T, et al. Among authors: moriya a. Liver Int. 2024 Mar 15. doi: 10.1111/liv.15907. Online ahead of print. Liver Int. 2024. PMID: 38488749
The Efficacy and Safety of Steroids for Preventing Postembolization Syndrome after Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.
Kuwaki K, Nouso K, Miyashita M, Makino Y, Hagihara H, Moriya A, Adachi T, Wada N, Yasunaka Y, Yasunaka T, Takeuchi Y, Onishi H, Nakamura S, Ikeda F, Shiraha H, Takaki A, Okada H. Kuwaki K, et al. Among authors: moriya a. Acta Med Okayama. 2019 Aug;73(4):333-339. doi: 10.18926/AMO/56935. Acta Med Okayama. 2019. PMID: 31439956 Free article. Clinical Trial.
38 results